Global and China Primary Cells Market
Global and China Primary Cells Market

Primary Cells Comprehensive Study by Type (Human Primary Cells, Animal Primary Cells), Origin (Hematopoietic, Blood, Skin, Gastrointestinal, Hepatocytes, Renal, Skeleton & Muscles), End User (Research Institute, Life Science Research Companies) Players and Region - Global Market Outlook to 2025

Primary Cells Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025 | CAGR: 6.81%  

Oct 2020 Edition 242 Pages 212 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Primary Cells Market Overview:
Primary cells are cells isolated from human or animal tissues. There are two type of primary cell such as human primary and animal primary cells. The global primary cell market will boost due to various usage in healthcare domain, mainly for cancer research. Primary cells show high physiological similarity to the tissues and organs they are extracted from. This offers vast help to researchers and scientists in understanding various complexities related to drug pathways, studying diseases and drug development. According to AMA, the Global Primary Cells market is expected to see growth rate of 6.81%

Growth Drivers
  • Increasing Demand in Cancer Research
  • Rising Pharmaceuticals Outsourcing

Market Trends
  • Up Surging Demand of Monoclonal Antibodies
  • Enlarging Biotechnology as well as Bio pharmaceutical Industries

Roadblocks
  • High Cost of Advance Primary Cell
  • Fueling Issues Regarding Primary Cell Culture Contamination

Opportunities
  • Lucrative Opportunities in Primary Cells in 3D Culture


Competitive Landscape:

Some of the key players profiled in the report are Thermo Fisher Scientific (United States), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics (United States), PromoCell (Germany), ZenBio (United States), STEMCELL Technologies (Canada), AllCells (United States), American Type Culture Collection (United States) and Axol Biosciences (United Kingdom). Additionally, following companies can also be profiled that are part of our coverage like Sigma-Aldrich (United States) and Cureline (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Primary Cells market by 2025. Considering Market by Origin, the sub-segment i.e. Hematopoietic will boost the Primary Cells market. Considering Market by End User, the sub-segment i.e. Research Institute will boost the Primary Cells market.

Latest Market Insights:
On 25th October 2018, Thermo Fisher Scientific Inc. (the global leader in serving science) has acquired Advanced Bioprocessing business from BD, a leading player of medical technology. The deal was established for 477 million dollar in cash.

On 22nd May 2018, Lonza has announced that the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio. and On 15th March 2018, Thermo Fisher Scientific (the global leader in serving science) has started The SyncD3 Webinar series, to observe the Offerings and Applications of Primary Cell Systems in New Educational Webinar.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Primary Cells market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Primary Cells market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Biologics, Distributors of Human and Animal Primary Cells, Research Laboratories, Cancer Research Organizations, Biopharmaceutical Firms, Healthcare Institutes, Medical Centers, Government and Other Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Human Primary Cells
  • Animal Primary Cells
By Origin
  • Hematopoietic
  • Blood
  • Skin
  • Gastrointestinal
  • Hepatocytes
  • Renal
  • Skeleton & Muscles

By End User
  • Research Institute
  • Life Science Research Companies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand in Cancer Research
      • 3.2.2. Rising Pharmaceuticals Outsourcing
    • 3.3. Market Trends
      • 3.3.1. Up Surging Demand of Monoclonal Antibodies
      • 3.3.2. Enlarging Biotechnology as well as Bio pharmaceutical Industries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Primary Cells, by Type, Origin, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Primary Cells (Value)
      • 5.2.1. Global Primary Cells by: Type (Value)
        • 5.2.1.1. Human Primary Cells
        • 5.2.1.2. Animal Primary Cells
      • 5.2.2. Global Primary Cells by: Origin (Value)
        • 5.2.2.1. Hematopoietic
        • 5.2.2.2. Blood
        • 5.2.2.3. Skin
        • 5.2.2.4. Gastrointestinal
        • 5.2.2.5. Hepatocytes
        • 5.2.2.6. Renal
        • 5.2.2.7. Skeleton & Muscles
      • 5.2.3. Global Primary Cells by: End User (Value)
        • 5.2.3.1. Research Institute
        • 5.2.3.2. Life Science Research Companies
      • 5.2.4. Global Primary Cells Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Primary Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lonza (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cell Biologics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PromoCell (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ZenBio (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. STEMCELL Technologies (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AllCells (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. American Type Culture Collection (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Axol Biosciences (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Primary Cells Sale, by Type, Origin, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Primary Cells (Value)
      • 7.2.1. Global Primary Cells by: Type (Value)
        • 7.2.1.1. Human Primary Cells
        • 7.2.1.2. Animal Primary Cells
      • 7.2.2. Global Primary Cells by: Origin (Value)
        • 7.2.2.1. Hematopoietic
        • 7.2.2.2. Blood
        • 7.2.2.3. Skin
        • 7.2.2.4. Gastrointestinal
        • 7.2.2.5. Hepatocytes
        • 7.2.2.6. Renal
        • 7.2.2.7. Skeleton & Muscles
      • 7.2.3. Global Primary Cells by: End User (Value)
        • 7.2.3.1. Research Institute
        • 7.2.3.2. Life Science Research Companies
      • 7.2.4. Global Primary Cells Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Primary Cells: by Type(USD Million)
  • Table 2. Primary Cells Human Primary Cells , by Region USD Million (2014-2019)
  • Table 3. Primary Cells Animal Primary Cells , by Region USD Million (2014-2019)
  • Table 4. Primary Cells: by Origin(USD Million)
  • Table 5. Primary Cells Hematopoietic , by Region USD Million (2014-2019)
  • Table 6. Primary Cells Blood , by Region USD Million (2014-2019)
  • Table 7. Primary Cells Skin , by Region USD Million (2014-2019)
  • Table 8. Primary Cells Gastrointestinal , by Region USD Million (2014-2019)
  • Table 9. Primary Cells Hepatocytes , by Region USD Million (2014-2019)
  • Table 10. Primary Cells Renal , by Region USD Million (2014-2019)
  • Table 11. Primary Cells Skeleton & Muscles , by Region USD Million (2014-2019)
  • Table 12. Primary Cells: by End User(USD Million)
  • Table 13. Primary Cells Research Institute , by Region USD Million (2014-2019)
  • Table 14. Primary Cells Life Science Research Companies , by Region USD Million (2014-2019)
  • Table 15. South America Primary Cells, by Country USD Million (2014-2019)
  • Table 16. South America Primary Cells, by Type USD Million (2014-2019)
  • Table 17. South America Primary Cells, by Origin USD Million (2014-2019)
  • Table 18. South America Primary Cells, by End User USD Million (2014-2019)
  • Table 19. Brazil Primary Cells, by Type USD Million (2014-2019)
  • Table 20. Brazil Primary Cells, by Origin USD Million (2014-2019)
  • Table 21. Brazil Primary Cells, by End User USD Million (2014-2019)
  • Table 22. Argentina Primary Cells, by Type USD Million (2014-2019)
  • Table 23. Argentina Primary Cells, by Origin USD Million (2014-2019)
  • Table 24. Argentina Primary Cells, by End User USD Million (2014-2019)
  • Table 25. Rest of South America Primary Cells, by Type USD Million (2014-2019)
  • Table 26. Rest of South America Primary Cells, by Origin USD Million (2014-2019)
  • Table 27. Rest of South America Primary Cells, by End User USD Million (2014-2019)
  • Table 28. Asia Pacific Primary Cells, by Country USD Million (2014-2019)
  • Table 29. Asia Pacific Primary Cells, by Type USD Million (2014-2019)
  • Table 30. Asia Pacific Primary Cells, by Origin USD Million (2014-2019)
  • Table 31. Asia Pacific Primary Cells, by End User USD Million (2014-2019)
  • Table 32. China Primary Cells, by Type USD Million (2014-2019)
  • Table 33. China Primary Cells, by Origin USD Million (2014-2019)
  • Table 34. China Primary Cells, by End User USD Million (2014-2019)
  • Table 35. Japan Primary Cells, by Type USD Million (2014-2019)
  • Table 36. Japan Primary Cells, by Origin USD Million (2014-2019)
  • Table 37. Japan Primary Cells, by End User USD Million (2014-2019)
  • Table 38. India Primary Cells, by Type USD Million (2014-2019)
  • Table 39. India Primary Cells, by Origin USD Million (2014-2019)
  • Table 40. India Primary Cells, by End User USD Million (2014-2019)
  • Table 41. South Korea Primary Cells, by Type USD Million (2014-2019)
  • Table 42. South Korea Primary Cells, by Origin USD Million (2014-2019)
  • Table 43. South Korea Primary Cells, by End User USD Million (2014-2019)
  • Table 44. Taiwan Primary Cells, by Type USD Million (2014-2019)
  • Table 45. Taiwan Primary Cells, by Origin USD Million (2014-2019)
  • Table 46. Taiwan Primary Cells, by End User USD Million (2014-2019)
  • Table 47. Australia Primary Cells, by Type USD Million (2014-2019)
  • Table 48. Australia Primary Cells, by Origin USD Million (2014-2019)
  • Table 49. Australia Primary Cells, by End User USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Primary Cells, by Type USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Primary Cells, by Origin USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific Primary Cells, by End User USD Million (2014-2019)
  • Table 53. Europe Primary Cells, by Country USD Million (2014-2019)
  • Table 54. Europe Primary Cells, by Type USD Million (2014-2019)
  • Table 55. Europe Primary Cells, by Origin USD Million (2014-2019)
  • Table 56. Europe Primary Cells, by End User USD Million (2014-2019)
  • Table 57. Germany Primary Cells, by Type USD Million (2014-2019)
  • Table 58. Germany Primary Cells, by Origin USD Million (2014-2019)
  • Table 59. Germany Primary Cells, by End User USD Million (2014-2019)
  • Table 60. France Primary Cells, by Type USD Million (2014-2019)
  • Table 61. France Primary Cells, by Origin USD Million (2014-2019)
  • Table 62. France Primary Cells, by End User USD Million (2014-2019)
  • Table 63. Italy Primary Cells, by Type USD Million (2014-2019)
  • Table 64. Italy Primary Cells, by Origin USD Million (2014-2019)
  • Table 65. Italy Primary Cells, by End User USD Million (2014-2019)
  • Table 66. United Kingdom Primary Cells, by Type USD Million (2014-2019)
  • Table 67. United Kingdom Primary Cells, by Origin USD Million (2014-2019)
  • Table 68. United Kingdom Primary Cells, by End User USD Million (2014-2019)
  • Table 69. Netherlands Primary Cells, by Type USD Million (2014-2019)
  • Table 70. Netherlands Primary Cells, by Origin USD Million (2014-2019)
  • Table 71. Netherlands Primary Cells, by End User USD Million (2014-2019)
  • Table 72. Rest of Europe Primary Cells, by Type USD Million (2014-2019)
  • Table 73. Rest of Europe Primary Cells, by Origin USD Million (2014-2019)
  • Table 74. Rest of Europe Primary Cells, by End User USD Million (2014-2019)
  • Table 75. MEA Primary Cells, by Country USD Million (2014-2019)
  • Table 76. MEA Primary Cells, by Type USD Million (2014-2019)
  • Table 77. MEA Primary Cells, by Origin USD Million (2014-2019)
  • Table 78. MEA Primary Cells, by End User USD Million (2014-2019)
  • Table 79. Middle East Primary Cells, by Type USD Million (2014-2019)
  • Table 80. Middle East Primary Cells, by Origin USD Million (2014-2019)
  • Table 81. Middle East Primary Cells, by End User USD Million (2014-2019)
  • Table 82. Africa Primary Cells, by Type USD Million (2014-2019)
  • Table 83. Africa Primary Cells, by Origin USD Million (2014-2019)
  • Table 84. Africa Primary Cells, by End User USD Million (2014-2019)
  • Table 85. North America Primary Cells, by Country USD Million (2014-2019)
  • Table 86. North America Primary Cells, by Type USD Million (2014-2019)
  • Table 87. North America Primary Cells, by Origin USD Million (2014-2019)
  • Table 88. North America Primary Cells, by End User USD Million (2014-2019)
  • Table 89. United States Primary Cells, by Type USD Million (2014-2019)
  • Table 90. United States Primary Cells, by Origin USD Million (2014-2019)
  • Table 91. United States Primary Cells, by End User USD Million (2014-2019)
  • Table 92. Canada Primary Cells, by Type USD Million (2014-2019)
  • Table 93. Canada Primary Cells, by Origin USD Million (2014-2019)
  • Table 94. Canada Primary Cells, by End User USD Million (2014-2019)
  • Table 95. Mexico Primary Cells, by Type USD Million (2014-2019)
  • Table 96. Mexico Primary Cells, by Origin USD Million (2014-2019)
  • Table 97. Mexico Primary Cells, by End User USD Million (2014-2019)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Primary Cells: by Type(USD Million)
  • Table 109. Primary Cells Human Primary Cells , by Region USD Million (2020-2025)
  • Table 110. Primary Cells Animal Primary Cells , by Region USD Million (2020-2025)
  • Table 111. Primary Cells: by Origin(USD Million)
  • Table 112. Primary Cells Hematopoietic , by Region USD Million (2020-2025)
  • Table 113. Primary Cells Blood , by Region USD Million (2020-2025)
  • Table 114. Primary Cells Skin , by Region USD Million (2020-2025)
  • Table 115. Primary Cells Gastrointestinal , by Region USD Million (2020-2025)
  • Table 116. Primary Cells Hepatocytes , by Region USD Million (2020-2025)
  • Table 117. Primary Cells Renal , by Region USD Million (2020-2025)
  • Table 118. Primary Cells Skeleton & Muscles , by Region USD Million (2020-2025)
  • Table 119. Primary Cells: by End User(USD Million)
  • Table 120. Primary Cells Research Institute , by Region USD Million (2020-2025)
  • Table 121. Primary Cells Life Science Research Companies , by Region USD Million (2020-2025)
  • Table 122. South America Primary Cells, by Country USD Million (2020-2025)
  • Table 123. South America Primary Cells, by Type USD Million (2020-2025)
  • Table 124. South America Primary Cells, by Origin USD Million (2020-2025)
  • Table 125. South America Primary Cells, by End User USD Million (2020-2025)
  • Table 126. Brazil Primary Cells, by Type USD Million (2020-2025)
  • Table 127. Brazil Primary Cells, by Origin USD Million (2020-2025)
  • Table 128. Brazil Primary Cells, by End User USD Million (2020-2025)
  • Table 129. Argentina Primary Cells, by Type USD Million (2020-2025)
  • Table 130. Argentina Primary Cells, by Origin USD Million (2020-2025)
  • Table 131. Argentina Primary Cells, by End User USD Million (2020-2025)
  • Table 132. Rest of South America Primary Cells, by Type USD Million (2020-2025)
  • Table 133. Rest of South America Primary Cells, by Origin USD Million (2020-2025)
  • Table 134. Rest of South America Primary Cells, by End User USD Million (2020-2025)
  • Table 135. Asia Pacific Primary Cells, by Country USD Million (2020-2025)
  • Table 136. Asia Pacific Primary Cells, by Type USD Million (2020-2025)
  • Table 137. Asia Pacific Primary Cells, by Origin USD Million (2020-2025)
  • Table 138. Asia Pacific Primary Cells, by End User USD Million (2020-2025)
  • Table 139. China Primary Cells, by Type USD Million (2020-2025)
  • Table 140. China Primary Cells, by Origin USD Million (2020-2025)
  • Table 141. China Primary Cells, by End User USD Million (2020-2025)
  • Table 142. Japan Primary Cells, by Type USD Million (2020-2025)
  • Table 143. Japan Primary Cells, by Origin USD Million (2020-2025)
  • Table 144. Japan Primary Cells, by End User USD Million (2020-2025)
  • Table 145. India Primary Cells, by Type USD Million (2020-2025)
  • Table 146. India Primary Cells, by Origin USD Million (2020-2025)
  • Table 147. India Primary Cells, by End User USD Million (2020-2025)
  • Table 148. South Korea Primary Cells, by Type USD Million (2020-2025)
  • Table 149. South Korea Primary Cells, by Origin USD Million (2020-2025)
  • Table 150. South Korea Primary Cells, by End User USD Million (2020-2025)
  • Table 151. Taiwan Primary Cells, by Type USD Million (2020-2025)
  • Table 152. Taiwan Primary Cells, by Origin USD Million (2020-2025)
  • Table 153. Taiwan Primary Cells, by End User USD Million (2020-2025)
  • Table 154. Australia Primary Cells, by Type USD Million (2020-2025)
  • Table 155. Australia Primary Cells, by Origin USD Million (2020-2025)
  • Table 156. Australia Primary Cells, by End User USD Million (2020-2025)
  • Table 157. Rest of Asia-Pacific Primary Cells, by Type USD Million (2020-2025)
  • Table 158. Rest of Asia-Pacific Primary Cells, by Origin USD Million (2020-2025)
  • Table 159. Rest of Asia-Pacific Primary Cells, by End User USD Million (2020-2025)
  • Table 160. Europe Primary Cells, by Country USD Million (2020-2025)
  • Table 161. Europe Primary Cells, by Type USD Million (2020-2025)
  • Table 162. Europe Primary Cells, by Origin USD Million (2020-2025)
  • Table 163. Europe Primary Cells, by End User USD Million (2020-2025)
  • Table 164. Germany Primary Cells, by Type USD Million (2020-2025)
  • Table 165. Germany Primary Cells, by Origin USD Million (2020-2025)
  • Table 166. Germany Primary Cells, by End User USD Million (2020-2025)
  • Table 167. France Primary Cells, by Type USD Million (2020-2025)
  • Table 168. France Primary Cells, by Origin USD Million (2020-2025)
  • Table 169. France Primary Cells, by End User USD Million (2020-2025)
  • Table 170. Italy Primary Cells, by Type USD Million (2020-2025)
  • Table 171. Italy Primary Cells, by Origin USD Million (2020-2025)
  • Table 172. Italy Primary Cells, by End User USD Million (2020-2025)
  • Table 173. United Kingdom Primary Cells, by Type USD Million (2020-2025)
  • Table 174. United Kingdom Primary Cells, by Origin USD Million (2020-2025)
  • Table 175. United Kingdom Primary Cells, by End User USD Million (2020-2025)
  • Table 176. Netherlands Primary Cells, by Type USD Million (2020-2025)
  • Table 177. Netherlands Primary Cells, by Origin USD Million (2020-2025)
  • Table 178. Netherlands Primary Cells, by End User USD Million (2020-2025)
  • Table 179. Rest of Europe Primary Cells, by Type USD Million (2020-2025)
  • Table 180. Rest of Europe Primary Cells, by Origin USD Million (2020-2025)
  • Table 181. Rest of Europe Primary Cells, by End User USD Million (2020-2025)
  • Table 182. MEA Primary Cells, by Country USD Million (2020-2025)
  • Table 183. MEA Primary Cells, by Type USD Million (2020-2025)
  • Table 184. MEA Primary Cells, by Origin USD Million (2020-2025)
  • Table 185. MEA Primary Cells, by End User USD Million (2020-2025)
  • Table 186. Middle East Primary Cells, by Type USD Million (2020-2025)
  • Table 187. Middle East Primary Cells, by Origin USD Million (2020-2025)
  • Table 188. Middle East Primary Cells, by End User USD Million (2020-2025)
  • Table 189. Africa Primary Cells, by Type USD Million (2020-2025)
  • Table 190. Africa Primary Cells, by Origin USD Million (2020-2025)
  • Table 191. Africa Primary Cells, by End User USD Million (2020-2025)
  • Table 192. North America Primary Cells, by Country USD Million (2020-2025)
  • Table 193. North America Primary Cells, by Type USD Million (2020-2025)
  • Table 194. North America Primary Cells, by Origin USD Million (2020-2025)
  • Table 195. North America Primary Cells, by End User USD Million (2020-2025)
  • Table 196. United States Primary Cells, by Type USD Million (2020-2025)
  • Table 197. United States Primary Cells, by Origin USD Million (2020-2025)
  • Table 198. United States Primary Cells, by End User USD Million (2020-2025)
  • Table 199. Canada Primary Cells, by Type USD Million (2020-2025)
  • Table 200. Canada Primary Cells, by Origin USD Million (2020-2025)
  • Table 201. Canada Primary Cells, by End User USD Million (2020-2025)
  • Table 202. Mexico Primary Cells, by Type USD Million (2020-2025)
  • Table 203. Mexico Primary Cells, by Origin USD Million (2020-2025)
  • Table 204. Mexico Primary Cells, by End User USD Million (2020-2025)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Primary Cells: by Type USD Million (2014-2019)
  • Figure 5. Global Primary Cells: by Origin USD Million (2014-2019)
  • Figure 6. Global Primary Cells: by End User USD Million (2014-2019)
  • Figure 7. South America Primary Cells Share (%), by Country
  • Figure 8. Asia Pacific Primary Cells Share (%), by Country
  • Figure 9. Europe Primary Cells Share (%), by Country
  • Figure 10. MEA Primary Cells Share (%), by Country
  • Figure 11. North America Primary Cells Share (%), by Country
  • Figure 12. Global Primary Cells share by Players 2019 (%)
  • Figure 13. Global Primary Cells share by Players (Top 3) 2019(%)
  • Figure 14. Global Primary Cells share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2019
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2019
  • Figure 20. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Lonza (Switzerland) Revenue: by Geography 2019
  • Figure 22. Cell Biologics (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cell Biologics (United States) Revenue: by Geography 2019
  • Figure 24. PromoCell (Germany) Revenue, Net Income and Gross profit
  • Figure 25. PromoCell (Germany) Revenue: by Geography 2019
  • Figure 26. ZenBio (United States) Revenue, Net Income and Gross profit
  • Figure 27. ZenBio (United States) Revenue: by Geography 2019
  • Figure 28. STEMCELL Technologies (Canada) Revenue, Net Income and Gross profit
  • Figure 29. STEMCELL Technologies (Canada) Revenue: by Geography 2019
  • Figure 30. AllCells (United States) Revenue, Net Income and Gross profit
  • Figure 31. AllCells (United States) Revenue: by Geography 2019
  • Figure 32. American Type Culture Collection (United States) Revenue, Net Income and Gross profit
  • Figure 33. American Type Culture Collection (United States) Revenue: by Geography 2019
  • Figure 34. Axol Biosciences (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Axol Biosciences (United Kingdom) Revenue: by Geography 2019
  • Figure 36. Global Primary Cells: by Type USD Million (2020-2025)
  • Figure 37. Global Primary Cells: by Origin USD Million (2020-2025)
  • Figure 38. Global Primary Cells: by End User USD Million (2020-2025)
  • Figure 39. South America Primary Cells Share (%), by Country
  • Figure 40. Asia Pacific Primary Cells Share (%), by Country
  • Figure 41. Europe Primary Cells Share (%), by Country
  • Figure 42. MEA Primary Cells Share (%), by Country
  • Figure 43. North America Primary Cells Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific (United States)
  • Merck KGaA (Germany)
  • Lonza (Switzerland)
  • Cell Biologics (United States)
  • PromoCell (Germany)
  • ZenBio (United States)
  • STEMCELL Technologies (Canada)
  • AllCells (United States)
  • American Type Culture Collection (United States)
  • Axol Biosciences (United Kingdom)
Additional players considered in the study are as follows:
Sigma-Aldrich (United States) , Cureline (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation